Received 20 April 2020 Revised 29 June 2020 Accepted 8 August 2020 DOI 101002lio2447 O R I G I N A L R E S E A R C H Comparing cellfree circulating tumor DNA mutational profiles diseasefree nonresponders patients oropharyngeal squamous cell carcinoma Alok R Khandelwal PhD12 Janmaris Marin Fermin MD1 Glenn Mills MD12 CherieAnn O Nathan MD12 Adam H Greer PhD2 Mickie Hamiter MD12 Thomas McMullen MD1 Tara MooreMedlin BS12 Jose M Flores MD34 Hong Yin PhD2 1Department OtolaryngologyHead Neck Surgery LSUHealth Shreveport Shreveport Louisiana 2FeistWeiller Cancer Center Shreveport Louisiana 3Department Epidemiology Johns Hopkins University Bloomberg School Public Health Baltimore Maryland 4LSUMedical Center Shreveport Louisiana Correspondence CherieAnn O Nathan MD Department OtolaryngologyHead Neck Surgery LSU Health Shreveport 1501 Kings Highway Shreveport LA 71130 Email cnathalsuhscedu Abstract Objective The purpose study investigate somatic non synonymous variants tumor tissue potentially identified circulating cell free DNA cfDNA head neck oropharyngeal squamous cell carcinoma OPSCC patients nextgeneration sequencing predict recurrence persistence disease Methods A total 22 OPSCC patients tumor tissue respective plasma samples included study Matching cfDNA tumor tissues processed DNA sequencing conducted MiSeq platform Variants identified Biomedical Genomic Workbench Genialiss online data analysis platform Swift Biosciences Accelamplicon panels Results Among 11 nonresponders 6 matched mutations detected 5 patients suggesting predictive factor patients likelihood recurrence The matched variants allele frequencies identified nonresponder group tumor DNAcfDNA TP53 G325fs 27062 TP53 R282W 48174 TP53 R273C 39217 FBXW7 R505G 3006 FBXW7 R505L 31065 TP53 Q331H 565052 Interestingly matched somatic mutations detected patients respond therapy persistent disease Conclusions Somatic nonsynonymous variants tumor tissue potentially identified cfDNA OPSCC patients NGS The likelihood variant detection cfDNA greater nonresponders especially human papillomavirusnegative nonresponders rendering beneficial invasive detection method disease persistencerecurrence prognosis Level evidence Cohort study Alok R Khandelwal Adam H Greer Mickie Hamiter contributed equally study This open access article terms Creative Commons AttributionNonCommercialNoDerivs License permits use distribution medium provided original work properly cited use noncommercial modifications adaptations 2020 The Authors Laryngoscope Investigative Otolaryngology published Wiley Periodicals LLC behalf The Triological Society 868 wileyonlinelibrarycomjournallio2 Laryngoscope Investigative Otolaryngology 20205868878 KHANDELWAL ET AL 869 K E Y W O R D S cfDNA oropharynx recurrence TP53 1 I N T RO DU CT I O N following criteria diagnosis OPSCC HPV HPV years 2008 2014 staging according American Joint Head neck squamous cell carcinomas HNSCC encompass Committee Cancer TNM staging eighth edition b available cancers arising mucosa oral cavity pharynx larynx plasma specimens matched flash frozen tumors c stage III IV HNSCC sixth leading common malignancy worldwide high rates mortality morbidity1 HNSCC accounts N1 disease d free distant metastases M0 Patients included study 2 years followup data 650 000 cases 330 000 deaths worldwide annually In United available Patients divided diseasefree non States estimated approximately 53 000 Americans responders standard therapy based radiographic data clini develop HNSCC annually 10 800 deaths occur tobacco alcohol use human papillomavirus HPV infection24 cal followup 2 years posttreatment Table 1 2 No statistically significant difference patient demographics observed Unfortunately 5year mortality rate stands approximately 50 diseasefree nonresponder groups suggesting Gaussian dis despite advances multimodal therapy past decades tribution patient samples The patients treated standard nonHPV associated cancers Furthermore prognosis therapy based National Comprehensive Cancer Network guidelines patients recurrent metastatic HNSCC generally poor The OPSCC httpswwwnccnorg The time recurrence persis median survival series 6 12 months depending tence nonresponder determined 0 117 months patient diseaserelated factors Thus need better average 26 months median 0 months For follow detection measures determine persistent recurrent disease mean value accounting groups 386 months potentially lead improved survival result salvage mean 306 months range 59 98 months surgery Circulating cellfree DNA cfDNA extracellular DNA circulating blood The presence cancerspecific genomic alterations 22 Sample preparation DNA extraction allows differentiation circular tumor DNA ctDNA DNA normal healthy cells Similar DNA apoptotic cells All specimens collected diagnosis treatment cfDNA consist range multiples 180 bp consistent unit size nucleosomes57 Recent studies identified increased levels circulating DNA fragments patients cancer813 Blood cells plasma separated centrifugation 2000 rpm 10 minutes stored locally 80cid1C freezer 10 minutes collection Circulating cfDNA extracted plasma Recent advances aided identifying epigenetic genetic characteristics HNSCC multiple data sets14 Leveraging informa tion genetic alterations applying context ctDNA carrying information tumorrelated genetic epigenetic Zymos QuickcfDNA Serum Plasma Kit according manu facturers protocol Briefly 15 3 mL plasma mixed SP 5 Digestion Buffer digested incubating Pro teinase K solution 55cid1C 30 minutes Postdigestion DNA changes help identify recurrences persistent disease lysate added volumes SP DNA Binding Buffer Our primary goal determine somatic nonsynonymous transferred ZymoSpin IIIS Column After centrifuging variants identified cfDNA OPSCC patients Further 1000g 2 minutes flowthrough discarded The column investigated extent mutations washed SP DNA Prep Buffer followed SP ctDNA correlated altered paired tumor tissues DNA Wash Buffer twice The cfDNA eluted DNA Elution Finally elucidated variants determined ctDNA correlated Buffer The size distribution extracted cfDNA examined response treatment recurrence persistent disease Agilent Tapestation 2200 highsensitivity D1000 tape In 2 M A T E R I A L S A N D M E T H O D S 21 Study design samples noncfDNA contamination removed Zymos SelectASize DNA Clean Concentrator kit The size distribution extracted cfDNA shown Figure 1Tissue DNA extracted flash frozen tissue NucleoSpin Tissue kit MACHEREY NAGEL GmbH Co KG Briefly 25 mg tissue ground digested proteinase K 56cid1C overnight lysed 70cid1C An Institutional Review Board approved retrospective study 10 minutes After grinding washing column DNA ducted 22 patients advanced squamous cell carcinoma eluted The quality genomic DNA tissue samples evalu oropharynx treated Louisiana State University Health Shreveport ated Agilent Tape station 2200 genomic tape HPV status determined based p16 immunohistochemistry Irrespective concentration cfDNA obtained patients IHC tumor samples Patients selected based 200 ng cfDNA analyses 870 KHANDELWAL ET AL T A B L E 1 Expected compared detected allele frequency QSeq HDx quantitative multiplex DNA reference standard CHR POS REF ALT Expected allele frequency Detected allele frequency N 4 SE Gene EGFR AA G719S PIK3CA H1047R KRAS NRAS BRAF KIT G13D Q61K V600E D816V PIK3CA E545K KRAS EGFR EGFR EGFR G12D L858R Î”R746A750 T790M 7 3 12 1 7 4 3 55241707 178952085 25398281 115256530 140453136 55599321 178936091 12 25398284 55259515 7 7 7 G A C G A A G C T A G T T T T A T G T 245 175 150 125 105 100 90 60 30 20 10 259 182 169 135 92 97 84 56 28 15 10 155 195 193 194 030 120 076 090 071 035 050 5524246555242479 Del 15 bp 55249071 C Note The detected allele frequency called Biomedical Genomic Workbench trimmed fastq files generated The average coverage set 1500 tissue DNA 10 000 cfDNA 24 Detection mutations cfDNA To identify variants DNA samples NGS prepared library AccelAmplicon 56G Oncology Panel v2 Swift Bio sciences This panel hotspot coverage 56 clinical oncologyrelated genes common mutations head neck cancer15 This panel uses 263amplicon design covering 16 000 mutations Furthermore panel requires input low 10 ng The average amplicon size 138 bp compatible size limitation cfDNA Also 95 ontarget specificity uniformity strengthen reliability panel First tested panel A QSeq HDx quantitative mul tiplex DNA reference standard HD701 This standard DNA contains 6 genes 11 variants expected allele frequency 1 245 The test results showed detected allele frequency 11 variants similar expected allele frequency Table 1 indicating panel generate reliable results meet standards F I G U R E 1 Cellfree DNA cfDNA size distribution cfDNA extracted plasma analyzed Agilent 2200 determine fragment size concentration 23 DNA sequencing 25 Bioinformatics analysis sequencing data Genomic DNA quantified Thermo Fishers Qubit 20 Qubit dsDNA HS Assay Kit CfDNA quantified quantative realtime Demultiplex fastq files analyzed work flows somatic polymerase chain reaction qPCR Alu primers Library pre cer work flow targeted amplicon sequencing Biomedical Geno pared Swift Biosciencess AccelAmplicon 56G Oncology Panel v2 mics Workbench BGW Qiagen Swift Bio AccelAmplicon panel Briefly 20 ng DNA amplified multiplex PCR gene pipelines Genialis GenialisIn somatic workflow BGW paired specific primers The PCR product size selected cleaned end reads imported BGW failed reads excluded SPRI select beads Beckman Coulter dualindexed according Illumina pipeline 18 later The primers trimmed Illuminas sequencing adapters After second size selection cleanup according primer list Swift Biosciences Reads aligned library quantified qPCR KAPA Library Quantification hg19 human reference genome A readytouse workflow Kits Roche A pairend DNA sequencing conducted Illuminas MiSeq platform MiSeq Reagent Kits v2 2 150 adapter targeted amplicon sequencing selected The default setting applied The QC reports variant calls targeting regions KHANDELWAL ET AL 871 generated according bed files AccelAmplicon 56G Oncology determined The Oncoprint ctDNA prepared Panel v2 A minimum frequency variant detection set 5 D3Oncoprint software Alida Palmisano Yingdong Zhao Richard tumor tissue 05 cfDNA sequencing data respectively Simon JCO Clinical Cancer Informatics 2018 nr 2 p 19 Through Swift Bio AccelAmplicon panel pipeline AccelAmplicon 56G Oncology Panel v2 fastq data aligned hg19 human reference genome Variants called GATK haplotype caller 26 Statistical analysis LoFreg Reported variant calls filtered read count read coverage frequency forwardreverse balance homopolymer Participants divided subgroups status nonsynonymous status Amino acid change reflecting relapse persistence b diseasefree non T A B L E 2 Patient clinicodemographic characteristics Age Age diagnosis median IQR Age diagnosis mean SD Diseasefree n 11 Nonresponder n 11 5500 4600 6300 55 4750 5900 5236 1071 54 852 Race Caucasian Black Gender Male Female Current smoker No Yes Tobacco use 7 64 4 36 10 91 1 9 6 55 5 45 8 73 3 27 7 64 4 36 2 18 9 82 Packyears median IQR Packyears mean SD Patient 10 packyears 1800 1000 3800 20 1500 3900 2705 2239 28 2028 No Yes Alcohol use No Yes HPV status Negative Positive Tumor stagea T1 T2 T3 T4 Nodal stage N1 N2 Squamous cell carcinoma pathology grade G2 moderately differentiated G3 poorly differentiated B3 poorly differentiated basaloid features aTNM staging according AJCC eighth edition 1 9 10 91 9 82 2 18 3 27 8 73 1 9 5 45 1 9 4 36 1 9 10 91 7 64 4 36 2 18 9 82 5 45 6 55 8 73 3 27 2 18 9 82 2 18 9 82 079 6 55 3 27 22 18 P value 85 100 31 18 58 100 18 0861 22 100 872 KHANDELWAL ET AL responders referring experience persistence recur negative diseasefree HPVnegative nonresponders rence Sociodemographic characteristics tumor characteristics HPV There significant difference TP53 mutation distribution status treatment variables measured Continuous variables HPVpositive HPVnegative group P 0075 Fishers presented mean SD categorical variables pres exact test Somatic mutant FBXW7 Fbox WD repeat domain ented number percentage patients P values continuous containing7 PTEN detected patients respectively variables correspond analysis variances P values categorical The somatic mutated PIK3CA HRAS CDKN2A variables fewer patients given category correspond patient gene All mutations previously Fishers exact test P values categorical variables reported head neck cancer consistent TCGA patients correspond Pearsons chisquare tests Data manage data Among 12 patients 3 patients 2 3 somatic mutations ment analyses performed STATASE statistical soft One HPVnegative nonresponder exhibited somatic mutations ware version 13 Stata Corp 3 R E S U L T S 31 Mutations cfDNA TP53 gene suggesting strengthening dysfunctions gene Further detected polymorphisms germline mutations 22 patients The frequent germline polymorphism genes 22 patients TP53 kinase insert domain Receptor KDR The polymorphism TP53 P72R occurred 16 22 patients The KDR polymorphism including Q472H V297I detected 15 patients Other observed germline mutations HINF1A 11 To validate liquid biopsies OPSCC patients sought isolate 22 PIK3CA 422 KIT 222 APC 222 CDKN2A 222 tumor DNA cfDNA blood samples obtained HNSCC patients matched corresponding tumor samples In current study 22 patients advancedstage squamous cell carci 33 Validation liquid biopsies noma oropharynx selected As shown Table 2 statistically significant differences patient demographics To validate liquid biopsies OPSCC patients determined age diagnosis race gender smoking status alcohol somatic mutations detected cfDNA We sequenced diseasefree nonresponders groups We evaluated cfDNA samples library preparation tissue viral status cohort percentage nonresponder samples Figure 1 To rid falsepositive variants combined different HPVpositive HPVnegative groups Consis variant callers loFreg BGW identify variants tent TCGA data nonresponders observed HPV allele frequency 1 according instruction AccelAmplicon negative group HPVpositive group Table 2 Addition 56G Oncology Panel v2 We excluded potential random errors ally tumor characteristics primary site tumor nodal recurrent background noise quadruple analyzing standard stage nonsignificant groups Table 2 DNA samples Among 22 cfDNA samples somatic variants detected 11 samples The variant number patient varied 1 6 variants The variant gene distribution patients 32 Identification mutations tumor cfDNA samples shown Figure 2 The variants EGFR genes detected patients Variants TP53 APC detected We panel prepare sequencing library tumor tis patients respectively CDKN2A Eerbb2 PIK3CA sue matched plasma DNA samples The quality sequencing data observed patients respectively evaluated FastQC coverage analysis performed To investigate cfDNA sequencing detect somatic muta BGW The average sequencing depth 22 tissue DNA samples 1600 The average percentage aligned reads target tissue DNA samples greater 95 The base coverage unifor mity 02 ranged 93 98 mean 96 The mean sequencing depth matched 22 cfDNA samples 12 000 The average percentage aligned reads target cfDNA sam ples 905 The mean base coverage uniformity 02 92 tions noted original tumor tissue somatic mutations allele frequency 05 identified callers listed Table 4 Analysis cfDNA revealed patients carried tumor sample bearded somatic mutations Table 4 patients HPVnegative nonresponders HPVpositive dis ease free Among somatic mutations detected tumor DNA samples TP53 mutants FBXW7 mutants CDNK2A mutant The sequencing data 22 tissue samples analyzed observed cfDNA samples The detected TP53 mutants BGW verified Genialiss Workflow Swift Biosciencess higher HPVnegative patients HPVpositive patients AccelAmplicon Panels Both germline somatic mutations deter P 0451 onetailed Fishers exact test The high incidence mined tumor tissue samples presented Table 3 A total TP53 mutants cfDNA samples HPVnegative patients 12 patients nonsynonymous somatic mutations determined correlated high incidence detected TP53 mutations tissue 22 patients The frequently occurred somatic mutant samples HPVnegative patients It suggests TP53 mutations gene TP53 detected patients Among important characteristic HPVnegative OPSCC patients HPVpositive diseasefree HPV patients KHANDELWAL ET AL 873 T A B L E 3 Germline somatic mutations determined tumor tissue samples ID Chr Region Type Reference Allele Frequency Read count Read coverage Gene Amino acid change HPVpositive responder 517 558 738 744 749 756 780 C332 3 178927410 17 7579472 4 4 55972974 55979558 17 7579472 4 4 12 17 4 9 12 17 17 3 4 55972974 55979558 121432117 7579472 153247289 21971160 121432117 7574012 7579472 178936082 55972974 17 7579472 4 3 4 12 17 3 4 10 17 55979558 178927410 55593464 121432117 7579472 178927410 55979558 89692905 7579548 SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV HPVpositive nonresponder 668 789 10 12 17 3 4 12 17 8972077989720780 Insertion 121432117 7579472 178927410 55979558 121432117 7579472 SNV SNV SNV SNV SNV SNV A G T C G T C G G G G G C G G T G C A A G G A C G G G G A C G G G C A T C A T C C C C C T C A A C T G C C C G T A A A C C G T C C 553 997 998 998 999 501 466 586 3854 3901 1113 938 3901 584 410 34 100 1364 305 544 438 194 999 163 491 525 621 506 27 239 2209 1415 1113 951 6983 3910 1115 940 1351 1162 884 56 1364 2026 779 80 1226 2211 8656 2268 1814 PIK3CA Ile391Met TP53 Pro72Arg KDR KDR TP53 KDR KDR Gln472His Val297Ile Pro72Arg Gln472His Val297Ile HNF1A Gly226Ala TP53 Pro72Arg FBXW7 Arg505Gly CDKN2A Arg81Gly HNF1A Gly226Ala TP53 TP53 Glu339Lys Pro72Arg PIK3CA Glu542Lys KDR TP53 Gln472His Pro72Arg 100 983 983 KDR Val297Ile 488 501 929 999 237 463 20 484 415 517 519 56 48 938 452 1564 1489 128 2131 3367 1315 546 2261 1847 58 1684 4137 1237 145 1231 3207 2980 137 2133 PIK3CA Ile391Met KIT Met541Leu HNF1A Gly226Ala TP53 Pro72Arg 14253 PIK3CA Ile391Met 2845 2800 4666 4456 113 3260 7385 2580 153 2746 KDR PTEN TP53 Val297Ile Arg130Gln Pro47Ser PTEN Asn311fs HNF1A Gly226Ala TP53 Pro72Arg PIK3CA Ile391Met KDR Val297Ile HNF1A Gly226Ala TP53 Pro72Arg Continues 874 T A B L E 3 Continued KHANDELWAL ET AL Chr Region Type Reference Allele Frequency Read count Read coverage Gene Amino acid change ID 807 SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV A T G G C C T G G G G G C G Deletion C SNV SNV SNV SNV SNV SNV SNV SNV SNV SNV T G C G G G G T C T 4 4 12 17 55593464 55972974 121432117 7579472 HPVnegative responder 723 766 C315 4 5 4 17 17 12 17 17 55979558 112173899 55972974 7578382 7579472 121432117 7578263 7579472 HPVnegative nonresponder 11 12 17 17 17 4 9 12 17 17 534289 121432117 7576872 7577574 7579472 55979558 21971017 121432117 7577094 7579472 4 55972974 17 7577046 4 55972974 460 499 606 662 767 817 836 17 7579442 Deletion G 9 4 4 21970979 55972946 55972974 17 17 7576853 7579472 4 4 55972974 153247288 12 121432117 SNV SNV SNV SNV SNV SNV SNV SNV C A T C G T C G C A C C T T A T C C A C A C C C T C C A C A A A A G A A C A A C 497 521 963 999 469 100 387 695 173 443 903 55 369 427 27 223 998 483 498 969 481 25 439 59 446 214 2092 1326 162 3057 714 1382 859 2047 259 85 6664 158 1956 58 889 294 2134 417 879 120 1119 257 664 158 765 358 4225 2550 159 3059 1521 1382 2213 2910 1520 192 7347 2702 5296 132 3260 1317 2136 859 1771 123 2331 1064 1509 2744 1714 1672 KIT KDR Met541Leu Gln472His HNF1A Gly226Ala TP53 Pro72Arg KDR APC KDR TP53 TP53 Val297Ile Pro870Ser Gln472His Ser183 Pro72Arg HNF1A Gly226Ala TP53 TP53 Arg196 Pro72Arg HRAS Gly12Cys HNF1A Gly226Ala TP53 TP53 TP53 Gly325fs Tyr236Cys Pro72Arg KDR Val297Ile CDKN2A Pro114Arg HNF1A Gly226Ala TP53 TP53 KDR TP53 KDR TP53 Arg282Trp Pro72Arg Gln472His Glu298 Gln472His Pro82fs 52 3112 5963 CDKN2A Ala127Ser 334 339 565 805 513 309 689 370 375 1646 914 924 762 58 1111 1109 2906 1153 1798 2467 84 KDR KDR TP53 TP53 Cys482Arg Gln472His Gln331His Pro72Arg KDR Gln472His FBXW7 Arg505Leu HNF1A Gly226Ala KHANDELWAL ET AL T A B L E 3 Continued 875 ID Chr Region Type Reference Allele Frequency Read count Read coverage Gene Amino acid change C312 17 17 4 5 12 17 7577121 7579472 55972974 112175711 121432117 7579472 SNV SNV SNV SNV SNV SNV G G T G G G A C A A C C 387 999 527 45 548 998 1460 1839 1130 1220 78 2060 3773 1841 2148 2706 143 2064 TP53 TP53 KDR APC Arg273Cys Pro72Arg Gln472His Ala1474Thr HNF1A Gly226Ala TP53 Pro72Arg Note Samples segregated based human papillomavirus HPV status response treatment F I G U R E 2 Oncoprint variants detected cellfree DNA cfDNA Variants picked described materials methods Frequency number patients cfDNA shown panel The right panel lists frequency number variant gene The solid dots dark pink indicate curated variant according Clinic Interpretation Variants Cancer CIViC FDAapproved drug target mutation My Cancer Genome OncoKB respectively 34 nonresponder groups Survival status diseasefree diseasefree group patients survived end time point study Considering distribution HPVpositive HPVnegative patients different diseasefree Kaplan Meier survival analysis diseasefree nonre nonresponders group Table 1 2 investigated survival sta sponders depicted Figure 3A Based survival curve tus HPVpositive HPVnegative patients The sur median survival nonresponder 186 months undefined vival analysis showed HPVpositive patients better 876 KHANDELWAL ET AL T A B L E 4 Matching mutation detected tissue DNA cellfree DNA cfDNA Sample ID Chr Region Type Tumor DNA ctDNA Gene AA Change Freq 5 Freq 05 cf460 cf499 cf744 cf817 cf836 17 17 4 17 4 17 7576872 7577094 153247289 7576853 153247288 7577121 Deletion SNV SNV SNV SNV SNV 270 481 305 565 309 387 062 174 06 052 065 218 TP53 TP53 FBXW7 TP53 FBXW7 TP53 G325fs R282W R505G Q331H R505L R273C F I G U R E 3 A KaplanMeier curves illustrating overall survival outcomes response status head neck oropharyngeal squamous cell carcinoma OPSCC patients Logrank MantelCox test P 0001 B KaplanMeier curves illustrating overall survival outcomes human papillomavirus HPV status OPSCC patients Logrank MantelCox test P 05 C Diseasefree survival cellfree DNA cfDNA detection P value 0668 onesided T test survival HPVnegative patients Figure 3B Two death 4 DI SCU SSION cases reported HPVpositive group death cases occurred HPVnegative group Therefore median sur Personalized pharmacogenomics strategies treating HNSCC vival HPVpositive patients undefined time compared patients require detection modulation potent mutations 2505 months HPVnegative patients To detection predict response therapy affect drug responses tissuematched ctDNA helps assess disease progression disease progression While genotyping tumor tissues help clini treatment analyzed diseasefree survival cal decisions certain extent conventional biopsies tempo ctDNApositive ctDNAnegative patients Figure 3C The rally spatially restricted brief insight provide average diseasefree survival 123 months ctDNApositive single region heterogeneous tumor tissue In addition patients 370 months ctDNAnegative patients Interest nonexistence consistent biomarkers currently tissue biop ingly ctDNApositive HPVnegative patients sies involving cytopathology histopathology patients recurred patient 8 months disease bone diagnosis clinical management head neck free followup cancers KHANDELWAL ET AL 877 The ctDNA promising emerging biomarker significant prior studies However ctDNA extremely diluted cfDNA FBXW7 sensitizes cancer cells radiation stabilizing p53 leading cell cycle arrest apoptosis20 Furthermore Tripathi et al multiple factors It challenging work true ctDNA demonstrated TP53 mutant cell lines unaltered FBXW7 sta lowfrequency level Several methods developed recently For detection unknown new tumorrelated variants clinic tus treated doxorubicin test drug resistance atten uated ability form clones invade21 Taken DNA limit detection allele frequency commercial available damage FBXW7mediated degradation p53 allows cell prolifera cfDNA sequencing kit set 05 1 order sensitiv tion recovery potentially negative effect ity reduce falsepositive errors In study cfDNA come treatment cancer disease sequenced Swift Biosciencess AccelAmplicon 56G Oncology Panel v2 This kit commercially available kits market cfDNA sequencing Though kit molecular barcoding 41 HPVnegative nonresponder mutations based limit detection allele frequency low 1 overall detection sensitivity ranged 94 100 The ampliconbased While mutations TP53 prominently associated onco kit high specificity ontarget reads 95 In analysis genesis significant observation present study differen tumor tissue bearded variants cfDNA samples expanded tial expression mutations diseasefree detection limit allele frequency 05 One reason lower detection limit variants known variants tumor tissue nonresponders groups therapy specific differentiation HPVpositive HPVnegative cases22 As previously reported Second detected lowfrequency variant AccelAmplicon 56G HPVnegative patients showed higher incidence TP53 Oncology kit verified sample samples ERASESeq Elimination Recurrent Artifacts Stochastic Errors method16 For newly mutations HPVpositive patients study The note worthy presence hotspot DNAbinding surface structural muta detected somatic variants cfDNA followed instruction tions TP53 R282W 48174 TP53 R273C 39217 manufacturer AccelAmplicon 56G Oncology Panel v2 The limit nonresponder group indicates effects highly destabilized detection set 1 Considering large number potential dysfunctional p53 mechanism patient group TP53 R282W cau falsepositive variants lowfrequency level variant called ses substantial destabilization mutant protein loss ther Lofreg BGW caller picked These variants modynamic stability 3 kcalmol consequently causing screened random recurrent errors quadruple analysis changes folding mutant protein making highly des standard DNA available cfDNA samples tabilized nonfunctional TP53 R273C mutation affects DNA We evaluated ctDNA OPSCC patient subgroups responding therapy comparison nonresponders While aspects contact functionality p53 protein ARG273 vital making key interactions phosphate backbone target DNA23 data study accordance prior studies indicat ing oncogenic mutations TP53 FBXW7 gene tumor tissues17 Thus mutation leads critical loss contact target DNA The presence TP53 R282W 48174 TP53 R273C study distinctively identified correlations non 39217 mutational effects nonresponder groups impli synonymous mutations ctDNA diseasefree nonre cate destabilized p53 mechanism factor therapeutic fail sponders groups OPSCC Among 11 nonresponders matched ure patients Furthermore presence mutations detected 4 patients suggesting predictive factor truncating mutation TP53 G325fs 27062 dysregulates p53 patients likelihood recurrence FBXW7 critical functionality promote tumorigenesis instead halting non tumor suppressor commonly deregulated responder groups implicates consequence tumorigenic mutant ubiquitinproteasome proteins human cancer A wide vari p53 significant nonresponder groups comparison ety FBXW7 substrates identified including oncoproteins responder group Consistent TCGA data nonresponders cyclin E cMyc Mcl1 mTOR Jun Notch AURKA undergo proteasomemediated degradation18 Furthermore recent observed HPVnegative group HPVpositive group Also substantially higher percentage matched TP53 muta studies highlighted importance FBXW7 promoting tions occurred 80 nonresponder patients Furthermore mitotic cell death help prevent premature escape mitosis mitotic slippage19 Mitotic slippage process cause study determined TP53 mutations 100 nonresponder HPVnegative HNSCC patients cohort chemoresistance tumor relapse Therefore studies Nevertheless studies suggest ctDNA potentially warranted identifying role FBXW7 HNSCC specific noninvasive liquid biomarker assess recurrence importantly nonresponding patients Interestingly exist advanced OPSCC patients especially HPVnegative patients cross talk FBXW7 p53 axis FBXW7 interacts p53 leads polyubiquitylation proteasomal degradation ACKNOWLEDG MENTS Interestingly increase FBXW7 reduced survival patients CherieAnn Nathan currently Associate Editor Laryngoscope wild type p53 patients carrying p53 mutation Investigate Otolaryngology Journal The project funded intra deletion suggesting tumorigenic effect FBXW7 amplifica mural grant FeistWeiller Cancer Center Shreveport tion dependent degradation functional p53 878 KHANDELWAL ET AL Louisiana We thank FeistWeiller Cancer Center LSU Health Shreveport providing funding support ORCID Mickie Hamiter httpsorcidorg0000000187327468 CherieAnn O Nathan httpsorcidorg000000017386318X RE FE R ENC E S 1 Siegel RL Miller KD Jemal A Cancer statistics 2018 CA Cancer J Clin 2018681730 2 Warnakulasuriya S Causes oral canceran appraisal controver sies Br Dent J 200920710471475 3 Chaturvedi AK Engels EA Pfeiffer RM et al Human papillomavirus rising oropharyngeal cancer incidence United States J Clin Oncol 2011293242944301 4 Chung CH Gillison ML Human papillomavirus head neck cer role pathogenesis clinical implications Clin Cancer Res 2009152267586762 5 Sidransky D Nucleic acidbased methods detection cancer Science 1997278534010541059 6 Leary RJ Sausen M Kinde I et al Detection chromosomal alter ations circulation cancer patients wholegenome sequencing Sci Transl Med 20124162162ra154 7 Aarthy R Mani S Velusami S Sundarsingh S Rajkumar T Role circu lating cellfree DNA cancers Mol Diagn Ther 2015196339350 8 Lochowska BA Nowak D Bialasiewicz P Cellfree tumour DNA diagnostic prognostic biomarker nonsmall cell lung carcinoma Adv Respir Med 2019872118122 9 Kato S SchwaederlÃ© MC Fanta PT et al Genomic assessment bloodderived circulating tumor DNA patients colorectal cers correlation tissue sequencing therapeutic response survival JCO Precis Oncol 20193116 10 Mithraprabhu S Morley R Khong T et al Monitoring tumour burden therapeutic response analysis circulating tumour DNA extracellular RNA multiple myeloma patients Leukemia 2019 3320222033 11 Yamamoto Y Uemura M Nakano K et al Increased level fragmen tation plasma circulating cellfree DNA diagnostic prognostic markers renal cell carcinoma Oncotarget 20189292046720475 12 Hamfjord J Guren TK Dajani O et al Total circulating cellfree DNA prognostic biomarker metastatic colorectal cancer prior line oxaliplatinbased chemotherapy Ann Oncol 20193010881095 13 Wang Y Zhao C Chang L et al Circulating tumor DNA analyses pre dict progressive disease indicate trastuzumabresistant mecha nism advanced gastric cancer EBioMedicine 201943261269 14 Choudhury JH Ghosh SK Promoter hypermethylation profiling iden tifies subtypes head neck Cancer distinct viral environ mental genetic survival characteristics PLoS One 2015106 e0129808 15 Stadler ME Patel MR Couch ME Hayes DN Molecular biology head neck cancer risks pathways Hematol Oncol Clin North Am 200822610991124 16 KampsHughes N McUsic A Kurihara L et al ERASESeq leveraging replicate measurements enhance ultralow frequency variant detec tion NGS data PLoS One 2018134e0195272 17 Cancer Genome Atlas N Comprehensive genomic characterization head neck squamous cell carcinomas Nature 20155177536576582 18 Richter KT Kschonsak YT Vodicska B Hoffmann I FBXO45 MYCBP2 regulates mitotic cell fate targeting FBXW7 degrada tion Cell Death Differ 201927758772 19 Yeh CH Bellon M Nicot C FBXW7 critical tumor suppressor human cancers Mol Cancer 2018171115 20 GalindoMoreno M GirÃ¡ldez S LimÃ³nMortÃ©s MC et al SCF FBXW7mediated degradation p53 promotes cell recovery UVinduced DNA damage FASEB J 201933101142011430 21 Tripathi V Kaur E Kharat SS et al Abrogation FBW7alpha dependent p53 degradation enhances p53s function tumor sup pressor J Biol Chem 2019294361322413232 22 Zhou G Liu Z Myers JN TP53 mutations head neck squamous cell carcinoma impact disease progression treatment response J Cell Biochem 20161171226822692 23 Kamaraj B Bogaerts A Structure function p53DNA com plexes inactivation rescue mutations molecular dynamics simulation study PLoS One 2015108e0134638 How cite article Khandelwal AR Greer AH Hamiter M et al Comparing cellfree circulating tumor DNA mutational profiles diseasefree nonresponders patients oropharyngeal squamous cell carcinoma Laryngoscope Investigative Otolaryngology 20205868878 httpsdoiorg101002lio2447